Investor Conference Call
Q3 2013 Results

October 31, 2013 / Marijn Dekkers, CEO
Disclaimer
This presentation may contain forward-looking statements based on current
assumptions and forecasts made by Bay...
Q3 2013 – Bayer Continues Encouraging
Business Development


Ongoing strong performance of Life Sciences, MaterialScience...
Q3 2013 –
Encouraging Business Development
Sales

EBIT

in € million
% currency & portfolio adj.

9,661

EBITDA

Core EPS
...
Q3 2013 – Regional Performance:
Growth Led By Emerging Economies
In € million, ∆% yoy Fx adjusted

Q3 2013 Group Sales by ...
Q3 2013 –
Cash Flow And Net Debt Development
Cash Flow in € million, Net Debt in € billion

Q3 2013 Cash Flow

GCF

NCF

N...
Q3 2013 – HealthCare: Organic Growth
Driven by New Products and Consumer Care
In € million, ∆% yoy, () = Fx & portf. adjus...
Q3 2013 – CropScience:
Good Start to the Season in Latin America
In € million, ∆% yoy, () = Fx & portf. adjusted

Sales
En...
Q3 2013 - MaterialScience:
On Prior-Year Level
In € million, ∆% yoy, () = Fx & portf. adjusted

Sales
Polycarbonates
-6% (...
FY 2013 Group Outlook Maintained
Although Increasingly Ambitious
Sales ∆ Fx and portfolio adjusted, EBITDA before special ...
Investor Conference Call
Q3 2013 Results

October 31, 2013 / Marijn Dekkers, CEO
Upcoming SlideShare
Loading in …5
×

Q3 2013 Investor Conference Call Presentation slides

869 views
708 views

Published on

Presentation charts for Q3 2013 Investor Conference Call on October 31, 2013

Published in: Business, Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
869
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
12
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Q3 2013 Investor Conference Call Presentation slides

  1. 1. Investor Conference Call Q3 2013 Results October 31, 2013 / Marijn Dekkers, CEO
  2. 2. Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 2 • Q3 2013 Investor Conference Call • Marijn Dekkers
  3. 3. Q3 2013 – Bayer Continues Encouraging Business Development  Ongoing strong performance of Life Sciences, MaterialScience level with prior-year quarter  New pharma product sales exceeding expectations, full-year target raised to >€1.4bn  Earnings significantly impacted by negative currency effects  Full-year 2013 Group outlook maintained although increasingly ambitious Page 3 • Q3 2013 Investor Conference Call • Marijn Dekkers
  4. 4. Q3 2013 – Encouraging Business Development Sales EBIT in € million % currency & portfolio adj. 9,661 EBITDA Core EPS in € million adjusted** in € million in € 9,643 1,842 1,984 1.27 1,221 1.17 828 Q3’12* Q3’13 +6% Q3’12* Q3’13 +47% Page 4 • Q3 2013 Investor Conference Call • Marijn Dekkers Q3’12* Q3’13 +8% Q3’12* Q3’13 +9% *Prior-year figures restated **before special items
  5. 5. Q3 2013 – Regional Performance: Growth Led By Emerging Economies In € million, ∆% yoy Fx adjusted Q3 2013 Group Sales by Region Emerging Economies¹ +9% USA +3% 20% Emerging Economies +1% +18% ~1,500 40% ~1,400 +11% 31% ~500 9% Western Europe +5% +6% ~400 Others² +8% Group €9,643m; +6% Page 5 • Q3 2013 Investor Conference Call • Marijn Dekkers Emerging Asia³ Latin America Eastern Europe Africa & Middle East ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia w/o Japan, Australia, New Zealand
  6. 6. Q3 2013 – Cash Flow And Net Debt Development Cash Flow in € million, Net Debt in € billion Q3 2013 Cash Flow GCF NCF Net Debt Development Investments oFCF -€1.3bn 7.7 1,367 ∆ y-o-y 9.0 1,728 514 1,214 +36% -13% +6% -19% June 30, 2013 Page 6 • Q3 2013 Investor Conference Call • Marijn Dekkers Sep 30, 2013
  7. 7. Q3 2013 – HealthCare: Organic Growth Driven by New Products and Consumer Care In € million, ∆% yoy, () = Fx & portf. adjusted Sales Consumer Health -3% (+3%) Earnings1 36% 1,924 Pharma +3% (+11%) 1,392 2,818 Adj. EBIT* Adj. EBITDA* +5% 1,331 915 +8% 1,006 1,048 +4% 847 633 HealthCare €4,742m; +1% (+7%) Price 0% Volume +8% Fx -8% Page 7 • Q3 2013 Investor Conference Call • Marijn Dekkers Portfolio +1% 484 477 +7% 371 -1% -1% 373 Q3‘12 Q3‘13 677 Q3‘12 Q3‘13 1 *before special items Prior-year figures restated.
  8. 8. Q3 2013 – CropScience: Good Start to the Season in Latin America In € million, ∆% yoy, () = Fx & portf. adjusted Sales Environmental Science +8% (+19%) 68 140 Earnings1 Crop Protection +6% (+14%) Adj. EBIT* Adj. EBITDA* 1,504 224 +14% 197 Seeds -30% (-30%) 115 +51% 76 CropScience €1,712m; +4% (+12%) Price +3% Volume +9% Fx -8% Page 8 • Q3 2013 Investor Conference Call • Marijn Dekkers Portfolio +1% Q3‘12 Q3‘13 Q3‘12 Q3‘13 1 *before special items Prior-year figures restated.
  9. 9. Q3 2013 - MaterialScience: On Prior-Year Level In € million, ∆% yoy, () = Fx & portf. adjusted Sales Polycarbonates -6% (-3%) Earnings1 Polyurethanes 0% (+4%) 673 1,567 337 CAS** -5% (+1%) Adj. EBIT* Adj. EBITDA* 346 +3% 486 174 IO*** -9% (-7%) 186 +7% 171 MaterialScience €2,897m; -3% (+1%) Price -1% Volume +2% Fx -4% Page 9 • Q3 2013 Investor Conference Call • Marijn Dekkers Portfolio 0% *before special items Q3‘12 Q3‘13 **CAS: Coatings, Adhesives, Specialties Q3‘12 Q3‘13 *** IO: Industrial Operations 1 Prior-year figures restated.
  10. 10. FY 2013 Group Outlook Maintained Although Increasingly Ambitious Sales ∆ Fx and portfolio adjusted, EBITDA before special items 20121 2013E Sales €39.7bn +4-5% to ~€40bn* adj. EBITDA €8.3bn mid-single-digit % increase Core EPS €5.30 high-single-digit % increase Page 10 • Q3 2013 Investor Conference Call • Marijn Dekkers *Assuming average Fx rates of 9M 2013 Outlook depends on specific planning assumptions as detailed in the Annual Report 1 2012 figures restated
  11. 11. Investor Conference Call Q3 2013 Results October 31, 2013 / Marijn Dekkers, CEO

×